Actavis plc announced an updated business structure for its U.S. Specialty Brands business designed to maximize the company's newly strengthened position in key therapeutic areas and position it for continued long-term growth. Under its new structure, Actavis' U.S. Specialty Brands business has been refocused as four business units - Women's Health, Urology/Gastroenterology (GI), Dermatology/Established Brands and Business Operations.

The company announced the appointment of Herm Cukier to lead the U.S. Specialty Brands Women's Healthcare category, Charles Sabino, Jr., to lead the U.S. Specialty Brands Urology and GI therapeutic category, and Thomas Griffin, Jr., to lead the Business Operations team. The four business unit leaders will report to Tim Callahan, Senior Vice President, Commercial Operations, who reports to Fred Wilkinson, President, Actavis Specialty Brands.
As General Manager, U.S. Women's Health, Mr. Cukier joins Actavis from Bayer, where he served most recently as Vice President, Marketing and Commercial Operations for Women's Healthcare. As General Manager, U.S. Urology and Gastroenterology, Mr. Sabino joins Actavis from Aptalis Pharma, where he most recently served as Vice President, Marketing for the specialty pharmaceutical company focused on Gastroenterology and Cystic Fibrosis treatments. Mr. Griffin has been with Actavis since 2011 as VP, Sales and Operations for the U.S. Specialty Brands business.